Objective: Thyroid cancer is increasing in incidence. Prostate-specific membrane antigen (PSMA) targeted radionuclide imaging and treatment demonstrated remarkable value in prostate cancer patients. Studies have shown that PSMA is also expressed in thyroid cancer. Our purpose is to evaluate the clinical usefulness of [Ga]Ga-PSMA-11 PET/CT for the diagnosis of thyroid cancer.
Methods: We enrolled 23 DTC and 17 RAIR-DTC patients prospectively. All patients underwent [Ga]Ga-PSMA-11 PET/CT and 2-[F]FDG PET/CT. PSMA expression was determined by immunohistochemistry on histological samples of lymphatic metastasis of 12 patients. We compared the detection rates and semi-quantitative parameters between [Ga]Ga-PSMA-11PET/CT and 2-[F]FDG PET/CT.
Results: A total of 72 lesions were detected. Detection rates of DTC and RAIR-DTC by [Ga]Ga-PSMA-11 PET/CT were lower than those by 2-[F]FDG PET/CT (60.00% 90.00%, = 0.004; 59.38% 96.88%). Compared with DTC, RAIR-DTC had higher semi-quantitative parameters of 2-[F]FDG PET/CT. There was no significant difference in semi-quantitative parameters of [Ga]Ga-PSMA-11 PET/CT between DTC and RAIR-DTC. Immunohistochemistry showed a significantly higher PSMA expression for RAIR-DTC than for DTC. However, there was no significant correlation between PSMA expression and SUVmax on Ga-PSMA [Ga]Ga-PSMA-11 PET/CT.
Conclusions: [Ga]Ga-PSMA-11 PET/CT can detect thyroid cancer metastases but its detection rate was lower than that of 2-[F]FDG PET/CT. There was a difference in PSMA expression levels between DTC and RAIR-DTC, but the difference was not reflected on [Ga]Ga-PSMA-11 PET/CT.
Advances In Knowledge: [Ga]Ga-PSMA-11 PET/CT has potential value in the diagnosis of thyroid cancer. [Ga]Ga-PSMA-11 PET/CT could screen out patients who may benefit from PSMA targeted radionuclide therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1259/bjr.20230291 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.
EJNMMI Radiopharm Chem
December 2024
Department of Nuclear Medicine, Saarland University - Medical Center, Kirrbergerstrasse, 66421, Homburg, Germany.
Background: The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting its metal complexation/radiolabeling properties making it an attractive building block for the development of multimeric/-valent radiopharmaceuticals. The objective of the study was to further explore the potential of the NOTI chelating platform by preparing and characterizing homotrimeric PSMA radioconjugates in order to identify a suitable candidate for clinical translation.
Results: Altogether, three PSMA conjugates based on the NOTI-TVA scaffold with different spacer entities between the chelating unit and the Glu-CO-Lys PSMA binding motif were readily prepared by solid phase-peptide chemistry.
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications.
BJR Open
January 2024
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW3 6JB, United Kingdom.
Objectives: To quantify the stage-shift with prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic prostate cancer and explore treatment implications.
Methods: Single-centre, retrospective analysis of patients with newly diagnosed [F]PSMA-1007 or [Ga]Ga-PSMA-11 PET/CT-detected metastatic prostate cancer who had baseline bone scintigraphy between January 2015 and May 2021. Patients were subclassified into oligometastatic and polymetastatic disease utilizing the STAMPEDE2 trial (ISRCTN66357938/NCT06320067) definition.
A novel androgen-independent radiotracer with dual targeting of NTSR1 and PSMA for PET/CT imaging of prostate cancer.
Eur J Med Chem
January 2025
Department of Nuclear Medicine, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, PR China. Electronic address:
A substantial proportion of patients with prostate cancer (PCa) develop treatment resistance or mortality after androgen deprivation therapy (ADT). Current methods for identifying and locating recurrent lesions using prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging, which relies on androgen levels, often result in diagnostic delays. Therefore, the development of an androgen-independent radiotracer is critical for the early identification of recurrent lesions.
View Article and Find Full Text PDFComparison of clinical performance between late and standard total-body [ Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China.
Article Synopsis
- Late [Ga]Ga-PSMA-11 PET/CT imaging shows improved lesion detection in prostate cancer compared to standard techniques, but its clinical use has been limited due to lower image quality with short axial field of view (SAFOV) systems.
- This study investigates the efficacy of late LAFOV [Ga]Ga-PSMA-11 PET/CT with forced diuresis, analyzing its diagnostic accuracy and effects on treatment decisions for patients with biochemical recurrence after prostate surgery.
- Findings reveal that late LAFOV PET/CT provides better image quality and a significantly higher rate of positive scans (80.31%) compared to standard scans (65.35%), indicating its potential to influence patient management.
Design, preclinical evaluation, and first-in-human PET study of [Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer.
Eur J Nucl Med Mol Imaging
November 2024
Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, 100875, China.
Purpose: Prostate cancer (PCa), characterized by tumor heterogeneity, may exhibit low or absent prostate-specific membrane antigen (PSMA) expression in cancerous lesions, limiting the detection sensitivity of monospecific probes. Given that fibroblast activation protein (FAP) is frequently overexpressed in the tumor microenvironment (TME), we developed a PSMA/FAP dual-targeting tracer to address this limitation.
Methods: The precursor (PSFA-01) was synthesized by coupling a quinolone-based FAP-targeting scaffold and EuK with HBED-CC via amide bonds.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!